Taltz?

Taltz is a brand-name prescription medication used to treat several autoimmune conditions [1]. It is an interleukin-17 (IL-17) inhibitor [1].

What conditions does Taltz treat?

Taltz is FDA-approved to treat:[1]
* Plaque psoriasis: For adults and children 6 years and older who are candidates for systemic therapy or phototherapy.
* Psoriatic arthritis: For adults who have active psoriatic arthritis.
* Ankylosing spondylitis: For adults with active ankylosing spondylitis.
* Non-radiographic axial spondyloarthritis: For adults with active non-radiographic axial spondyloarthritis and objective signs of inflammation.
* Ustekinumab-treated inadequately active psoriatic arthritis: For adults who have had an inadequate response or intolerance to ustekinumab.

How does Taltz work?

Taltz works by blocking the activity of IL-17A, IL-17F, and IL-17AF cytokines [1]. These cytokines are believed to play a key role in the inflammation associated with plaque psoriasis and psoriatic arthritis [1]. By inhibiting these proteins, Taltz helps reduce inflammation and the associated symptoms of these conditions [1].

What is the active ingredient in Taltz?

The active ingredient in Taltz is ixekizumab [1].

When does the patent for Taltz expire?

The patent landscape for Taltz is complex and involves multiple patents covering different aspects of the drug, including composition of matter, methods of use, and manufacturing processes. According to DrugPatentWatch.com, the earliest expected patent expiry for Taltz is in late 2029, with others extending into the 2030s [2]. These dates can be subject to change due to patent challenges, extensions, and regulatory approvals [2].

Can biosimilars be approved before patent expiry?

While biosimilar applications can be filed and reviewed before a patent expires, the biosimilar cannot be approved for marketing until the relevant patents have expired or have been successfully challenged and invalidated [3]. The pathway for biosimilar approval involves demonstrating similarity to the reference product and does not automatically grant market entry if patents remain in force [3].

Who manufactures Taltz?

Taltz is manufactured by Eli Lilly and Company [1].

What are the common side effects of Taltz?

Common side effects of Taltz include upper respiratory tract infections, injection site reactions, and fungal infections (such as thrush) [1]. Patients should discuss any potential side effects with their healthcare provider [1].

Where can I find more information about Taltz and its patents?

More detailed information on Taltz, including its patent status and potential for generic or biosimilar competition, can be found on DrugPatentWatch.com [2].

---
Sources:

[1] https://www.taltz.com/
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/